Andrea Califano is Professor of Systems Biology at Columbia University, in the Department of Biochemistry and Molecular Biophysics, Biomedical Informatics, and in the Institute for Cancer Genetics. Since 2010, he is founding director and chair of the Columbia Initiative in Systems Biology, slated for departmental status later in 2011. He is also Director of the Sulzberger Columbia Genome Center and Associate Director for Bioinformatics of the Herbert Irving Comprehensive Cancer Center.
Dr. Califano's interests are broadly defined within the field of Systems Biology, with specific application to human malignancies. In particular his lab has pioneered early efforts to assemble genome-wide, context-specific maps of molecular interactions in human cells, using reverse engineering algorithms and high-throughput experimental approaches. Interrogation of these maps has led to the rational elucidation of master regulators of both physiological and pathological phenotypes, as well as of the driving mutations and aberrant signals that are integrated by these genes. Over the last few years, the Califano lab has assembled biochemically validated, genome-wide map of transcriptional and post-transcriptional interaction in several human cell contexts, including B cell, Breast Carcinoma, Glioma, as well as normal and tumor-related Stem Cells. The Califano lab integrates the development of analytical methodologies with high-throughput experimental assays necessary for data generation and biochemical/biological validation.
Dr. Califano serves on several boards in academia, industry, and government. among these, he is a member of the Board of Scientific Advisors of the National Cancer Institute, the Physical Science Oncology Center (Dana Farber Cancer Institute), the Center for a Virtual Tumor (Harvard), the Skin Cancer SPORE (Yale University), the CardioVascular Resarch Grid (Johns Hopkins), and Sage Bionetworks. He was for 13 years at IBM Research where he directed the IBM Computational Biology Center. He was the founder and chief technology officer of First Genetic Trust, and Founder and Chairman of Therasis Inc. The latter is a company recently founded in New York for the systems biology based development of combination therapy for human malignancies.